SEC Form 4 · accession 0000891293-17-000106
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirske
Officer — EVP, Chief Financial Officer
Period of report
Sep 29, 2017
Accepted (ET)
Oct 3, 2017 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $3.19 | Sep 29, 2017 | A | 315,000 | A | — | Sep 29, 2027 | Common Stock | 315,000 | 315,000 | D |
Explanation of responses
- F1The stock options will vest in six equal semi-annual installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates.